Proprietary Endosome-to-Cytosol Delivery (ECD) technology that enhances intracellular delivery of small molecules, antisense oligonucleotides, proteins and nanoparticle-based drugs. Offers partners and collaborators a delivery platform to enable next-generation therapeutics development for human health.